LB Pharmaceuticals Inc
LBRXNasdaqCIK 1691082HealthcareFiscal year ends Dec 31
Reports and events: 27 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1512:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-391358 |
| 2026-09-0312:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-381076 |
| 2026-08-1112:10 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-343490 |
| 2026-08-1112:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343479 |
| 2026-07-2912:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-322208 |
| 2026-07-2212:14 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-311357 |
| 2026-06-1020:16 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-265867 |
| 2026-06-0920:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-263724 |
| 2026-05-1220:31 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219607 |
| 2026-05-1220:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219529 |
| 2026-04-2320:06 ET | DEF 14A | Proxy statementPeriod 2026-06-03 | 0001193125-26-173679 |
| 2026-04-0620:05 ET | S-1 | Registration statement | 0001193125-26-143724 |
| 2026-03-2620:32 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-126368 |
| 2026-03-2620:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-126223 |
| 2026-03-1620:40 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-108474 |
| 2026-03-1012:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-099419 |
| 2026-02-1021:30 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001193125-26-044781 |
| 2026-02-0513:15 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-038539 |
| 2025-11-1313:15 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-279074 |
| 2025-11-1213:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-276070 |
| 2025-11-0613:23 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-268174 |
| 2025-11-0613:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-268154 |
| 2025-09-2514:55 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-25-091474 |
| 2025-09-1920:30 ET | SCHEDULE 13D | Ownership report, active investor | 0001193125-25-209153 |
| 2025-09-1220:06 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-202195 |
| 2025-09-0814:03 ET | S-1/A | Registration statement, amended | 0001193125-25-197877 |
| 2025-08-2220:49 ET | S-1 | Registration statement | 0001193125-25-186467 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.